Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry.
The objective of the Registry was to characterize the population of infants receiving prophylaxis for respiratory syncytial virus (RSV) disease by describing the patterns and scope of usage of palivizumab in a cross section of US infants. RSV hospitalization outcomes were also described. The Palivizumab (Synagis, MedImmune, Inc., 25 West Watkins Mill Road, Gaithersburg, MD 20878) Outcomes Registry was a prospective multicenter survey conducted at 63 sites. Demographics, injection history, and RSV hospitalization outcomes were collected on 2,116 infants receiving palivizumab. Infants were enrolled in the Registry between September 1, 2000-March 1, 2001, at the time of their first injection. Infants born at less than 32 weeks of gestation accounted for 47% of infants enrolled, and those between 32-35 weeks accounted for 45%; approximately 8% were greater than 35 weeks of gestation. Lower RSV hospitalization rates were observed in infants who had greater adherence to regularly scheduled injections. Nearly one-half of all hospitalizations occurred within the first and second injection intervals, suggesting the importance of early RSV protection. The confirmed RSV hospitalization rate of all infants in the Registry was 2.9%; the rate was 5.8% in infants with chronic lung disease of infancy, and 2.1% in premature infants without chronic lung disease. In conclusion, these data support the continued effectiveness of palivizumab prophylaxis for severe RSV lower respiratory tract disease in a large cohort of high-risk infants from geographically diverse pediatric offices and clinics. The Palivizumab Outcomes Registry provides an opportunity to assess palivizumab utilization and clinical effectiveness in the US.
Parnes
Curt
C
Guillermin
Judith
J
Habersang
Rolf
R
Nicholes
Peggy
P
Chawla
Vijay
V
Kelly
Tammy
T
Fishbein
Judith
J
McRae
Patty
P
Goessler
Mary
M
Gatti
Antoinette
A
Calcagno
John A
JA
Eki
Cheryl
C
Harris
Kristen A
KA
Joyave
Joseph
J
McFarland
Kathy
K
Protter
Paul
P
Sullivan
Mary
M
Stanford
Allan
A
Lovett
Nancy
N
Ortiz
Marisol
M
Rojas
Sharon
S
Cyrus
Scott
S
Cyrus
Janell
J
Cohen
Stuart
S
Buchin
Debbie
D
Riordan
Linda
L
Zuniga
Monica
M
Shah
Rupa
R
Minard
Carmen
C
Quintin
Arden
A
Douglas
Glenda
G
van Houten
John
J
Freutner
Sharyn
S
Chartrand
Stephen
S
Nowatzke
Patsy
P
Romero
Jose
J
Rhodes
Torunn
T
Benoit
Michelle
M
Walter
Emmanuel
E
Walker
Leslie
L
DeBonnett
Laurie
L
Cross
Mia
M
Free
Teresa
T
Martin
Sharman
S
Shank
Karen
K
Guedes
Ben
B
Atkinson
Lee Ann
LA
Halpin
George J
GJ
Rouse
Kathy
K
Hand
Ivan
I
Geiss
Donna
D
Marshall
James R
JR
Burleson
Lois
L
Boland
Jim
J
Seybold
Kelsey
K
Hunter
Vicki
V
Unfer
Susan
S
Schmucker
Jackie
J
Gley
Margaret
M
Marcus
Michael
M
Thompson
Patricia
P
Milla
Paulino
P
Young
Connie
C
Zanni
Robert
R
Zinno
Virginia
V
Fetter-Zarzeka
Alexandra
A
Busey
Amanda
A
Sokunbi
Modupe A
MA
Airington
Sherrie
S
Richard
Nancy
N
Muraligopal
Vellore
V
Lewis
Stephanie
S
Weber
F Thomas
FT
Giordano
Beverly P
BP
Linehan
Denise
D
Roach
Jane
J
Davis
Randle
R
Rzepka
Andrew A
AA
Booth
Teri
T
Smeltzer
David
D
Walsh
Jeanne
J
Arispe
Emilio
E
Rowley
Rhonda
R
Bolling
Christopher
C
Botts
Tanya
T
Haskett
Kateri
K
Raby
Deana
D
Batiz
Evelyn
E
Gelfand
Andrew
A
Farrell
Lynn
L
Butler
Stephen
S
Colby
Linda
L
Schochet
Peter
P
Bentler
Julie
J
Hirsch
David
D
Wilkinson
Lisa
L
Aaronson
Allen
A
Bennett
Eleanora
E
Wingate
Julie
J
Quinn
Dawn
D
Komendowski
Katherine
K
Deckard
Marcia
M
Frogel
Michael
M
Nerwen
Cliff
C
Copenhaver
Steven
S
Prater
Michele
M
Wolsztein
Jacob
J
Mackey
Kristine
K
Benbow
Marshall
M
Naranjo
Marisela
M
Hensley
Sandra
S
Hayes
Cindy
C
Sadeghi
Hossein
H
Lawson
Sally May
SM
McCall
Mark
M
Combs
Karla
K
Ledbetter
Joel
J
Sarnosky
Karen
K
Swafford
Cathy
C
Speer
Michael
M
Barton
Wendy J
WJ
Mink
J W
JW
Lemm
Dianne
D
Hudak
Mark
M
Case
Elizabeth
E
Rowen
Judith
J
Fuentes
Sandra
S
Pane
Carly
C
Richardson
Leslie
L
Chavarria
Cesar
C
Cassino
Deanne
D
Ghaffari
Kourosh
K
Carroll
Carol
C
Lee
Haesoon
H
Guclu
Lydia
L
Johnson
Christopher
C
Blum
Valerie
V
Boron
Marnie L
ML
Sorrentino
Mark
M
Hirsch
Robert L
RL
Van Veldhuisen
Paul C
PC
Smith
Carol
C
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006760:Hospitalization; D006801:Humans; D007223:Infant; D008297:Male; D000069455:Palivizumab; D011446:Prospective Studies; D012042:Registries; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy / Q000517:prevention & control*; D012307:Risk Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab